In the present study, we tested the therapeutic efficacy of rhMG53 in models of AD and observed enhanced neuronal membrane repair, reduced neurotoxicity, and limited cell death in ex vivo APP/PS1 mouse brain tissue and Aβ42-treated cultured neuronal cell types. This evidence concerns the gene APP and Alzheimer disease.